Jan Astermark

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

Jan Astermark, Sharyne Donfield, Donna DiMichele et al. · Blood · 2006 · 467 citations · Full text

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

P. Collins, Victor S. Blanchette, Kathelijn Fischer et al. · Journal of Thrombosis and Haemostasis · 2008 · 320 citations

Factor Viii Levels, Medicine, Hematology +7

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

Steven W. Pipe, Frank W.G. Leebeek, Michael Recht et al. · New England Journal of Medicine · 2023 · 307 citations · Full text

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

Jan Astermark, Pia Petrini, Lilian Tengborn et al. · British Journal of Haematology · 1999 · 279 citations · Full text

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

Erik Berntorp, Jan Astermark, Sven Björkman et al. · Haemophilia · 2003 · 270 citations · Full text

Consensus Summary, Preventive Medicine, Secondary Prophylaxis +14